High-dose Sulbactam Treatment for Ventilator-Associated Pneumonia Caused by Carbapenem-Resistant Acinetobacter Baumannii
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Several antibiotics can be used to treat ventilator-associated pneumonia caused by carbapenem-resistant A. baumannii (CRAB-VAP) including high-dose sulbactam. However, the effectiveness of high-dose sulbactam therapy is not well known. We report our experience with high-dose sulbactam for treatment of CRAB-VAP. Methods: Medical records of patients with CRAB-VAP who were given high-dose sulbactam between May 2013 and June 2015 were reviewed. Results: Fifty-eight patients with CRAB-VAP were treated with high-dose sulbactam. The mean age was 72.0 ± 15.2 years, and the acute physiology and chronic health evaluation II (APACHE II) score was 15.1 ± 5.10 at the time of CRAB-VAP diagnosis. Early clinical improvement was observed in 65.5% of patients, and 30-day mortality was 29.3%. Early clinical failure (odds ratio [OR]: 8.720, confidence interval [CI]: 1.346-56.484; p = 0.023) and APACHE II score ≥ 14 at CRAB-VAP diagnosis (OR: 10.934, CI: 1.047-114.148; p = 0.046) were associated with 30-day mortality. Conclusions: High-dose sulbactam therapy may be effective for the treatment of CRAB-VAP. However, early clinical failure was observed in 35% of patients and was associated with poor outcome.
Abstract
Background: Several antibiotics can be used to treat ventilator-associated pneumonia caused by carbapenem-resistant A. baumannii (CRAB-VAP) including high-dose sulbactam. However, the effectiveness of high-dose sulbactam therapy is not well known. We report our experience with high-dose sulbactam for treatment of CRAB-VAP. Methods: Medical records of patients with CRAB-VAP who were given high-dose sulbactam between May 2013 and June 2015 were reviewed. Results: Fifty-eight patients with CRAB-VAP were treated with high-dose sulbactam. The mean age was 72.0 ± 15.2 years, and the acute physiology and chronic health evaluation II (APACHE II) score was 15.1 ± 5.10 at the time of CRAB-VAP diagnosis. Early clinical improvement was observed in 65.5% of patients, and 30-day mortality was 29.3%. Early clinical failure (odds ratio [OR]: 8.720, confidence interval [CI]: 1.346-56.484; p = 0.023) and APACHE II score ≥ 14 at CRAB-VAP diagnosis (OR: 10.934, CI: 1.047-114.148; p = 0.046) were associated with 30-day mortality. Conclusions: High-dose sulbactam therapy may be effective for the treatment of CRAB-VAP. However, early clinical failure was observed in 35% of patients and was associated with poor outcome.
참고문헌 (31)
- Dijkshoorn L, "An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii", Nat Rev Microbiol, 5, pp.939~951 (2007)
- Lortholary O, "Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis", Clin Infect Dis, 20, pp.790~796 (1995)
- Jawad A, "Influence of relative humidity and suspending menstrua on survival of Acinetobacter spp. on dry surfaces", J Clin Microbiol, 34, pp.2881~2887 (1996)
- Fournier PE, "The epidemiology and control of Acinetobacter baumannii in health care facilities", Clin Infect Dis, 42, pp.692~699 (2006)
- Castanheira M, "Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options", Clin Infect Dis, 59(6), pp.S367~S373 (2014)
- Halstead DC, "Antimicrobial susceptibility among Acinetobacter calcoaceticusbaumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial", J Infect, 55, pp.49~57 (2007)
- Karageorgopoulos DE, "Tigecycline for the treatment of multidrugresistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence", J Antimicrob Chemother, 62, pp.45~55 (2008)
- Kumazawa J, "The history of antibiotics:the Japanese story", Infect Chemother, 8, pp.125~133 (2002)
- Pogue JM, "Incidence of and risk factors for colistinassociated nephrotoxicity in a large academic health system", Clin Infect Dis, 53, pp.879~884 (2011)
- Rocco M, "Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and", or other nephrotoxic antibiotics: a retrospective cohort study, 2013, pp.17, R174~
- Traub WH, "Antimicrobial drug susceptibility of clinical isolates of Acinetobacter species (A. baumannii, A. haemolyticus, genospecies 3, and genospecies 6)", Antimicrob Agents Chemother, 33, pp.1617~1619 (1989)
- Vila J, "In vitro antimicrobial production of beta-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii", Antimicrob Agents Chemother, 37, pp.138~141 (1993)
- Fishbain J, "Treatment of Acinetobacter infections", Clin Infect Dis, 51, pp.79~84 (2010)
- Jellison TK, "Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam", Pharmacotherapy, 21, pp.142~148 (2001)
- Henwood CJ, "Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936)", J Antimicrob Chemother, 49, pp.479~487 (2002)
- Knaus WA, "APACHE II: a severity of disease classification system", Crit Care Med, 13, pp.818~829 (1985)
- Pugin J, "Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic “blind” bronchoalveolar lavage fluid", Am Rev Respir Dis, 143(5 Pt 1), pp.1121~1129 (1991)
- Vincent JL, "The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction", failure. On behalf of the working group on sepsis-related problems of the European society of intensive care medicine, 1996, pp.22, 707~710
- Bou G, "Fast assessment of resistance to carbapenems and ciprofloxacin of clinical strains of Acinetobacter baumannii", J Clin Microbiol, 50, pp.3609~3613 (2012)
- Levey AS, "A new equation to estimate glomerular filtration rate", Ann Intern Med, 150, pp.604~612 (2009)
- Franklin R, "Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement M100-S21" (2011), Clinical and Laboratory Standards Institute
- Betrosian AP, "Efficacy and safety of high-dose ampicillin", sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia, 2008, pp.56, 432~436
- Betrosian AP, "High-dose ampicillin sulbactam as an alternative treatment of late-onset VAP from multidrugresistant Acinetobacter baumannii", Scand J Infect Dis, 39, pp.38~43 (2007)
- Wood GC, "Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia", Clin Infect Dis, 34, pp.1425~1430 (2002)
- Levin AS, "Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin", sulbactam, 2003, pp.21, 58~62
- Kim WY, "Comparable efficacy of tigecycline versus colistin therapy for multidrug-resistant and extensively drug-resistant Acinetobacter baumannii pneumonia in critically ill patients", PLoS One, 11, pp.e0150642~ (2016)
- Durante-Mangoni E, "Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drugresistant Acinetobacter baumannii: a multicenter, randomized clinical trial", Clin Infect Dis, 57, pp.349~358 (2013)
- Abdellatif S, "Efficacy and toxicity of aerosolized colistin in ventilator-associated pneumonia: a prospective, randomized trial", Ann Intensive Care, 6, pp.26~ (2016)
- Garnacho-Montero J, "Treatment of multidrug-resistant Acinetobacter baumannii ventilatorassociated pneumonia (VAP) with intravenous colistin:a comparison with imipenem-susceptible VAP", Clin Infect Dis, 36, pp.1111~1118 (2003)
- Esperatti M, "Validation of predictors of adverse outcomes in hospital-acquired pneumonia in the ICU", Crit Care Med, 41, pp.2151~2161 (2013)
- Chan JD, "Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia", J Intensive Care Med, 25, pp.343~348 (2010)